OCT 21, 2016 12:04 PM PDT

Bone Marrow Drug Dramatically Reverses Baldness

WRITTEN BY: Xuan Pham

A new drug may lift hopes for many people plagued with a certain type of hair loss. In clinical trials, researchers have demonstrated dramatic reversal of hair loss in 75 percent of patients after treatment with ruxolitinib, a JAK inhibitor. While promising, there are several caveats to the success of this drug. However, researchers and hair loss patients are hopeful the new drugs can soon be adapted or translated to other more common types of hair loss.

Our hair is extremely personal and is part of our expression of our identity. But for the millions of people suffering from hair loss (alopecia), this form of expression is limited. One type of alopecia, alopecia areata, results from the autoimmune attack on hair follicles.
 
Previously, researchers studying this disease reported that certain immune cells in the Janus kinase (JAK) pathway seemed to be responsible for the hair loss. They hypothesized that inhibiting the JAK family of enzymes could reawaken the damaged and dormant hair follicles to induce hair growth.
 
Indeed, in a small clinical trial with 12 patients with mild to moderate alopecia areata, the results seemed to corroborate this hypothesis. The patients were prescribed 20 mg of ruxolitinib, an FDA-approved JAK inhibitor, for 6 months. At the end of the study, 9 out of 12 patients had greater than 50 percent of hair regrowth. In fact, the results were closer to 95 percent of hair regrowth among those who responded to treatment.
 
“Although our study was small, it provides crucial evidence that JAK inhibitors may constitute the first effective treatment for people with alopecia areata,” said Julian Mackay-Wiggan, the study's lead author. “This is encouraging news for patients who are coping with the physical and emotional effects of this disfiguring autoimmune disease.”
 

Importantly, hair regrowth was dependent on taking ruxolitinib continually. Among those who stopped medication, hair loss returned. “Our findings suggest that initial treatment induces a high rate of disease remissions in patients with moderate to severe alopecia areata but maintenance therapy may be needed,” said Mackay-Wiggan.
 
Ruxolitinib is already approved by the FDA for other diseases, such as bone marrow malignancies and rheumatoid arthritis. And while there were no major side effects noted in this small study, researchers found that participants had a weaker immune system while on the drug, which made them susceptible to more illnesses.
 
As dramatic as the before-and-after evidence may be, the celebration does not yet include people who suffer from androgenic alopecia (also known as male or female pattern baldness), which is the most common kind of baldness. However, researchers agree that this is an excellent step forward in understanding how to treat the other types of hair loss conditions.
 
“We expect JAK inhibitors to have widespread utility across many forms of hair loss based on their mechanism of action in both the hair follicle and immune cells,” said co-author Dr.Angela M. Christiano, a professor of genetics and development and dermatology at Columbia.

Additional sources: Columbia University Medical Center

Image credit: Mackay-Wiggan et al. 2016, JCI Insight

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 23, 2019
Clinical & Molecular DX
AUG 23, 2019
Are Anti-Ebola Drugs Effective?
A deadly Ebola Virus Disease (EVD) caused by the Ebola virus triggers hemorrhagic fever in humans and some monkeys. The disease is highly infectious and is...
SEP 02, 2019
Clinical & Molecular DX
SEP 02, 2019
A Blood Drop Test for Rapid Detection of Traumatic Brain Injury
A study published by Yue et al., in August 2019, reported that a simple blood test (a few drops of blood) can detect traumatic brain injury efficiently and...
NOV 07, 2019
Neuroscience
NOV 07, 2019
Reading, Hearing Language Connects Meaning to Same Region in the Brain
Scientists at the University of California Berkeley used improved functional MRI resolution to show that similar neural circuits in the same regions of the...
JAN 14, 2020
Clinical & Molecular DX
JAN 14, 2020
Can I eat this donut? A quick test for celiac disease.
Genetic testing revealed that our ancestors have been eating wheat, rye, spelt and barley for over 8,000 years. Today, gluten, a protein found within these...
JAN 22, 2020
Clinical & Molecular DX
JAN 22, 2020
Biosignatures detect TB infections months before symptoms appear
What if there was a test that could detect tuberculosis six months before symptoms appear? Researchers at the University of College London think a predicti...
FEB 22, 2020
Clinical & Molecular DX
FEB 22, 2020
Harmful Algal Blooms
Algae is an essential plant-like organism. They contribute to the diet of some marine animals and supply necessary oxygen to bodies of water. Algae populat...
Loading Comments...